Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

被引:78
作者
Yamada, S [1 ]
Onda, M [1 ]
Kato, S [1 ]
Matsuda, N [1 ]
Matsuhisa, T [1 ]
Yamada, N [1 ]
Miki, M [1 ]
Matsukura, N [1 ]
机构
[1] Nippon Med Coll, Dept Surg 1, Bunkyo Ku, Tokyo 1138603, Japan
关键词
CYP2C19; single nucleotide polymorphisms; Helicobacter pylori; proton pump inhibitor;
D O I
10.1007/s005350170029
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background This study was designed to compare genetic differences in single-nucleotide polymorphisms of the S-mephenytoin 4'-hydroxylation (CYP2C19) gene among four Asian populations. Methods. Polymerase chain reaction with restriction fragment length polymorphism (PCR-RFLP) analysis of CYP2C19 was conducted in Japanese, Chinese, Thai, and Vietnamese populations. All genotype frequencies were analyzed. Wild-type homozygote and wild-type heterozygote genotypes were extensive proton pump inhibitor (PPI) metabolizers. Mutant-type heterozygote and mutant-type homozygote genotypes were poor PPI metabolizers. Results. No significant differences in CYP2C19 phenotype, calculated based on genotype frequencies, (P > 0.05) were found among the four populations. Conclusions. Many factors, including CYP2C19 polymorphisms, affect the success rate of Helicobacter pylori eradication with PPI-based therapy. We suspect that CYP2C19 polymorphisms may not be the main factor associated with differences among these four Asian populations in the success rates of H. pylori eradication with PPI-based therapy.
引用
收藏
页码:669 / 672
页数:4
相关论文
共 21 条
  • [1] Pharmacokinetics and effect an caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
    Andersson, T
    Holmberg, J
    Röhss, K
    Walan, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (04) : 369 - 375
  • [2] Aoyama N, 1999, J GASTROENTEROL, V34, P80
  • [3] THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY
    BALIAN, JD
    SUKHOVA, N
    HARRIS, JW
    HEWETT, J
    PICKLE, L
    GOLDSTEIN, JA
    WOOSLEY, RL
    FLOCKHART, DA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) : 662 - 669
  • [4] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
  • [5] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [6] Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
    Furuta, T
    Ohashi, K
    Kamata, T
    Takashima, M
    Kosuge, K
    Kawasaki, T
    Hanai, H
    Kubota, T
    Ishizaki, T
    Kaneko, E
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) : 1027 - 1030
  • [7] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
    Goldstein, JA
    Ishizaki, T
    Chiba, K
    deMorais, SMF
    Bell, D
    Krahn, PM
    Evans, DAP
    [J]. PHARMACOGENETICS, 1997, 7 (01): : 59 - 64
  • [8] Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian
    Inoue, K
    Yamazaki, H
    Shimada, T
    [J]. XENOBIOTICA, 1998, 28 (04) : 403 - 411
  • [9] High and variable frequencies of CYP2C19 mutations:: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands
    Kaneko, A
    Lum, JK
    Yaviong, J
    Takahashi, N
    Ishizaki, T
    Bertilsson, L
    Kobayakawa, T
    Björkman, A
    [J]. PHARMACOGENETICS, 1999, 9 (05): : 581 - 590
  • [10] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396